FindTrial
Sign In

A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00287521
Enrollment
87
Registered
2006-02-07
Start date
2005-11-30
Completion date
2006-02-28
Last updated
2012-03-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ocular Hypertension, Open-angle Glaucoma

Keywords

open, angle, glaucoma, ocular, hypertension

Brief summary

The purpose of this study is to determine whether a glaucoma therapy is safe and effective in treating patients with open-angle glaucoma or ocular hypertension.

Interventions

DRUGAL-37807 Ophthalmic Suspension, 1.0%

One drop in the study eye(s) once daily for 28 days

DRUGLatanoprost, 0.005% (Xalatan)

One drop in the study eye(s) once daily for 28 days

OTHERAL-37807 Vehicle

One drop in the study eye(s) once daily for 28 days

DRUGTimolol Maleate Ophthalmic Gel Forming Solution, 0.5%

One drop in the study eye(s) once daily for 28 days

Sponsors

Alcon Research
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Diagnosed with open-angle glaucoma (with ot without pseudoexfoliation or pigment dispersion component) or ocular hypertension * Other protocol-defined inclusion criteria may apply.

Exclusion criteria

* Under 18 * Other protocol-defined

Design outcomes

Primary

MeasureTime frame
Mean intra-ocular pressure (IOP) change at Day 28 from baseline (Day 0)Day 28

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026